AESARA HEOR Benchmarking Report: 2024
Capability
Health Economics and Outcomes Research in the biopharmaceutical industry has grown significantly
Environment
Investments in HEOR are driven by stakeholder demands for timely evidence of product value worldwide
Need
HEOR Groups must optimize their structure, evidence generation efforts, and marketplace impact
AESARA HEOR Benchmarking Report: 2024
Insights on how Biopharma companies rank among their peers, strengths and weaknesses of HEOR organizations, and areas for improvement in value and evidence generation to enable patient access
Description
This 2024 benchmark is based on qualitative and quantitative data from:
-7 biopharmaceutical companies
-60+ interviews conducted with HEOR leaders and team members worldwide
Interviewee representation from:
Global, USA, EU, Japan, Canada, UK
The report focuses on:
- Organization structure and positioning
- Teams characteristics
- Capabilities and infrastructure
- Ways of Working
- AESARA insights and recommendations
-7 biopharmaceutical companies
-60+ interviews conducted with HEOR leaders and team members worldwide
Interviewee representation from:
Global, USA, EU, Japan, Canada, UK
The report focuses on:
- Organization structure and positioning
- Teams characteristics
- Capabilities and infrastructure
- Ways of Working
- AESARA insights and recommendations
